TissGeneSummary for RGS16 |
Gene summary |
Basic gene information | Gene symbol | RGS16 |
Gene name | regulator of G-protein signaling 16 | |
Synonyms | A28-RGS14|A28-RGS14P|RGS-R | |
Cytomap | UCSC genome browser: 1q25-q31 | |
Type of gene | protein-coding | |
RefGenes | NM_002928.3, | |
Description | hRGS-rregulator of G-protein signalling 16retinal-specific RGSretinally abundant regulator of G-protein signaling | |
Modification date | 20141207 | |
dbXrefs | MIM : 602514 | |
HGNC : HGNC | ||
Ensembl : ENSG00000143333 | ||
HPRD : 03945 | ||
Vega : OTTHUMG00000035212 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_RGS16 | |
BioGPS: 6004 | ||
Pathway | NCI Pathway Interaction Database: RGS16 | |
KEGG: RGS16 | ||
REACTOME: RGS16 | ||
Pathway Commons: RGS16 | ||
Context | iHOP: RGS16 | |
ligand binding site mutation search in PubMed: RGS16 | ||
UCL Cancer Institute: RGS16 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Thyroid gland | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | THCA | |
Reference showing the relevant tissue of RGS16 | ||
Description by TissGene annotations | Risk TissGene in OS Cancer gene |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for RGS16 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LUSC | 1.925401325 | 3.25971309 | -1.334311765 | 2.38E-08 | 7.18E-08 |
KICH | 3.343823443 | 1.335263443 | 2.00856 | 2.22E-05 | 6.56E-05 |
THCA | 2.967270019 | 4.840864934 | -1.873594915 | 1.93E-17 | 3.96E-16 |
COAD | 1.506164674 | -0.549608403 | 2.055773077 | 1.57E-10 | 2.11E-09 |
KIRP | -0.491173307 | 1.007995443 | -1.49916875 | 0.000131 | 0.000433829 |
Top |
TissGene-miRNA for RGS16 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for RGS16 |
TissGeneSNV for RGS16 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.R22H | LIHC | 1 |
p.W95* | LUAD | 1 |
p.L162Q | LIHC | 1 |
p.M142I | HNSC | 1 |
p.S174L | UCEC | 1 |
p.K41R | STAD | 1 |
p.E129K | BLCA | 1 |
p.S30L | BLCA | 1 |
p.P169S | BRCA | 1 |
p.S65W | PRAD | 1 |
p.T140M | STAD | 1 |
p.E198K | SKCM | 1 |
p.S88N | KICH | 1 |
p.I132V | LUAD | 1 |
p.A149S | UCEC | 1 |
p.A155V | UCEC | 1 |
p.G24V | BLCA | 1 |
p.R178W | BRCA | 1 |
p.T140M | PRAD | 1 |
p.F19L | KICH | 1 |
p.A97T | UCEC | 1 |
p.E129X | SKCM | 1 |
p.L60P | STAD | 1 |
p.A16V | LUSC | 1 |
p.A154V | PAAD | 1 |
p.T39I | UCEC | 1 |
p.S174L | SKCM | 1 |
p.F19L | BRCA | 1 |
p.A154V | BLCA | 1 |
p.P127L | SKCM | 1 |
p.E129* | SKCM | 1 |
Top |
TissGeneCNV for RGS16 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for RGS16 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for RGS16 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for RGS16 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for RGS16 |
TissGeneDrug for RGS16 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for RGS16 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0027627 | Neoplasm Metastasis | 2 | BeFree |
umls:C0007137 | Squamous cell carcinoma | 1 | GAD |
umls:C0009402 | Colorectal Carcinoma | 1 | BeFree |
umls:C0018671 | Head and Neck Neoplasms | 1 | GAD |
umls:C0027643 | Neoplasm Recurrence, Local | 1 | GAD |
umls:C0027819 | Neuroblastoma | 1 | BeFree |
umls:C0036341 | Schizophrenia | 1 | GAD |
umls:C0085183 | Neoplasms, Second Primary | 1 | GAD |
umls:C0178874 | Tumor Progression | 1 | BeFree |
umls:C0235974 | Pancreatic carcinoma | 1 | BeFree |
umls:C0346647 | Malignant neoplasm of pancreas | 1 | BeFree |
umls:C0685938 | Malignant neoplasm of gastrointestinal tract | 1 | BeFree |
umls:C0686619 | Secondary malignant neoplasm of lymph node | 1 | BeFree |
umls:C0700095 | Central neuroblastoma | 1 | BeFree |
umls:C1458155 | Mammary Neoplasms | 1 | BeFree |
umls:C1527249 | Colorectal Cancer | 1 | BeFree |